Acuta Capital Partners’s Ultragenyx Pharmaceutical RARE Stock Holding History

Acuta Capital Partners’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-23,814	Closed	-$866K	–	31
2025 Q2	$866K	Buy	23,814 +2,524	+12%	+$91K	1.21%	22
2025 Q1	$771K	Buy	21,290 +290	+1%	+$12.1K	0.89%	27
2024 Q4	$883K	Sell	21,000 -4,100	-16%	-$203K	0.89%	29
2024 Q3	$1.39M	Buy	+25,100	New	+$1.28M	1.13%	25
2024 Q2	–	Sell	-20,000	Closed	-$934K	–	40
2024 Q1	$934K	Buy	+20,000	New	+$943K	0.61%	30

Other funds holding RARE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Acuta Capital Partners's RARE Position: Q3 2025 in Review

Acuta Capital Partners sold out of Ultragenyx Pharmaceutical (RARE) in Q3 2025, closing a stake of 23,814 shares — an estimated $866K sold.

Acuta Capital Partners first reported a position in RARE in Q1 2024 and held it in 5 quarters. The position peaked at $1.39M in Q3 2024. 302 funds tracked by Wall St. Rank hold RARE as of Q3 2025.

Acuta Capital Partners reported no remaining Ultragenyx Pharmaceutical position as of Q3 2025 after selling out during the quarter.
Acuta Capital Partners sold 23,814 Ultragenyx Pharmaceutical shares in Q3 2025, an estimated $866K.
Acuta Capital Partners first reported a position in Ultragenyx Pharmaceutical in Q1 2024 and held it in 5 quarters.
Acuta Capital Partners's Ultragenyx Pharmaceutical position peaked at $1.39M in Q3 2024.
302 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q3 2025.

Based on Acuta Capital Partners's 13F filing for Q3 2025, filed 14 Nov 2025.